Merck expanded a multi‑year collaboration with Tempus to apply Tempus’ de‑identified clinical and molecular datasets and AI tooling to discover precision oncology biomarkers and mechanisms of resistance, aiming to accelerate drug development decisions. Separately, Vanderbilt Health entered a research and co‑development collaboration with Korean proteomics company Bertis to integrate spatial molecular AI with proteomics and metabolomics for target and biomarker discovery in oncology. Both deals reflect continued industry investment in multimodal datasets and AI-driven biomarker platforms to de‑risk development programs and inform patient selection strategies.